Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Batefenterol/FF vs Placebo in COPD
NCT02573870Phase 2Completed
- Sponsor
- GSK
- Start
- Dec 2015
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Batefenterol/FF with Placebo (2 arms). Primary endpoint: Change From Baseline in 0 to 4 Hours Post-dose Weighted Mean Heart Rate at Day 42. Started Dec 2015; status: completed.
02
Drugs
batefenterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02573870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02573870.